|
Final Director's Interest Notice - C. Mews
|
29 June 2023 at 10:05am
|
|
Initial Director's Interest Notice - B. Mitchell
|
29 June 2023 at 10:05am
|
|
Appointment of Independent Non-Executive Director
|
29 June 2023 at 9:40am
|
|
Settlement of Wangara Facility
|
13 June 2023 at 10:15am
|
|
March 2023 Quarterly Activities and Cashflow Reports
|
28 April 2023 at 3:30pm
|
|
Wangara Facility Sale
|
4 April 2023 at 9:40am
|
|
AusCann to Partially Divest Animal Health Assets
|
10 March 2023 at 12:50pm
|
|
Appendix 4D and Half-Year Financial Report 31 December 2022
|
28 February 2023 at 3:45pm
|
|
December 2022 Quarterly Activities and Cashflow Reports
|
31 January 2023 at 2:55pm
|
|
Final Director's Interest Notice
|
3 January 2023 at 9:55am
|
|
Resignation of Non-Executive Director
|
3 January 2023 at 9:55am
|
|
Results of Annual General Meeting
|
30 November 2022 at 12:55pm
|
|
Market Update for Shareholders
|
30 November 2022 at 9:50am
|
|
September 2022 Quarterly Activities and Cashflow Reports
|
31 October 2022 at 8:50pm
|
|
Notice of Annual General Meeting/Proxy Form
|
28 October 2022 at 5:05pm
|
|
Letter to Shareholders - Notice of Annual General Meeting
|
28 October 2022 at 5:05pm
|
|
Annual Report
|
28 October 2022 at 4:50pm
|
|
Annual Financial Statements
|
30 September 2022 at 5:25pm
|
|
Appendix 4G and Corporate Governance Statement
|
30 September 2022 at 5:10pm
|
|
2022 Annual General Meeting - Key Dates
|
30 September 2022 at 4:20pm
|
|
Resignation of Chief Executive Officer
|
13 September 2022 at 10:30am
|
|
Increase to EuroCann Facility & Sale of Wangara Premises
|
9 September 2022 at 12:05pm
|
|
Suspension from Official Quotation
|
31 August 2022 at 7:30pm
|
|
Appendix 4E
|
31 August 2022 at 6:25pm
|
|
Appointment of CFO
|
12 August 2022 at 5:59pm
|
|
June 2022 Quarterly Activities and Cashflow Reports
|
29 July 2022 at 5:45pm
|
|
March 2022 Quarterly Activities and Cashflow Reports
|
29 April 2022 at 4:35pm
|
|
AusCann to Expand into European Cannabis Market
|
29 April 2022 at 10:30am
|
|
Notification of cessation of securities - AC8
|
1 April 2022 at 7:45pm
|
|
Resignation of Chief Financial Officer
|
11 March 2022 at 3:35pm
|
|
Appendix 4D and Half-Year Financial Report 31 December 2021
|
28 February 2022 at 5:50pm
|
|
Notification regarding unquoted securities - AC8
|
17 February 2022 at 9:40am
|
|
AusCann Receives Positive MOC from the U.S. FDA for CPAT-01
|
8 February 2022 at 11:25am
|
|
December 2021 Quarterly Activities and Cashflow Reports
|
28 January 2022 at 9:25am
|
|
AusCann Advances DermaCann Registration & US Launch
|
15 December 2021 at 10:05am
|
|
Initial Director's Interest Notice - T. McGrouther
|
15 December 2021 at 10:05am
|
|
Final Director's Interest Notice x 2
|
15 December 2021 at 9:59am
|
|
Appointment of New Chairperson and Director Resignations
|
14 December 2021 at 10:15am
|
|
AusCann Completes Successful Meeting with the U.S. FDA
|
9 December 2021 at 10:35am
|
|
Final Director's Interest Notice x 2
|
16 November 2021 at 9:30am
|
|
AusCann Board Changes
|
16 November 2021 at 8:40am
|
|
Results of Annual General Meeting
|
15 November 2021 at 5:45pm
|
|
Annual General Meeting - CEO Presentation
|
15 November 2021 at 3:00pm
|
|
Annual General Meeting - Chairman's Address
|
15 November 2021 at 2:50pm
|
|
AusCann to Commence Cannabinoid Trial in Spinal Cord Injury
|
12 November 2021 at 8:55am
|
|
Change of Director's Interest Notice - K. Bates
|
10 November 2021 at 4:55pm
|
|
Quarterly Cashflow and Market Update September 2021
|
28 October 2021 at 9:25am
|
|
AusCann Requests Formal Meeting with the FDA-CVM for CPAT-01
|
18 October 2021 at 10:10am
|
|
Annual Report
|
14 October 2021 at 10:20am
|
|
Letter to Shareholders - Notice of Annual General Meeting
|
14 October 2021 at 10:20am
|
AusCann Group Holdings Ltd